✦ LIBER ✦

Phase II trial of topotecan in patients with cisplatin-refractory germ cell tumors

✍ Scribed by Heidi Sonya Puc; Dean F. Bajorin; George J. Bosl; Alison Amsterdam; Robert J. Motzer

Publisher: Springer US
Year: 1995
Tongue: English
Weight: 171 KB
Volume: 13
Category: Article
ISSN: 0167-6997
DOI: 10.1007/bf00872866

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II trial of paclitaxel in refrac

A phase II trial of paclitaxel in refractory germ cell tumors

✍ Alan B. Sandler; Antonios Cristou; Susan Fox; Stephen D. Williams; Craig R. Nich 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 78 KB 👁 2 views

over 24 hours every 21 days without growth factor support. The median age of the patients was 32.5 years (range, 18-49 years). The testis was the primary site of Genitourinary Oncology Program, Indiana Unitumor for 13 patients (72%) and the tumor was extragonadal in 5 patients (28%).

Phase II trial of topotecan in patients

Phase II trial of topotecan in patients with advanced renal cell carcinoma

✍ Teresa Murray Law; David H. Ilson; Robert J. Motzer 📂 Article 📅 1994 🏛 Springer US 🌐 English ⚖ 159 KB

Treatment of patients with cisplatin-ref

Treatment of patients with cisplatin-refractory testicular germ-cell cancer

✍ Carsten Bokemeyer; Christian Kollmannsberger; Andreas Harstrick; Jörg Beyer; Art 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 French ⚖ 78 KB 👁 2 views

With the use of cisplatin-based combination chemotherapy, metastatic testicular germ-cell tumors can be cured in 70% to 80% of patients. The combination of cisplatin, etoposide and bleomycine (PEB) is considered standard therapy.

Phase II study of iproplatin (CHIP) in p

Phase II study of iproplatin (CHIP) in patients with cisplatin-refractory germ cell tumors; the need for alternative strategies in the investigation of new agents in GCT

✍ Barbara A. Murphy; Robert J. Motzer; George J. Bosl 📂 Article 📅 1992 🏛 Springer US 🌐 English ⚖ 281 KB

Phase II trial of carboplatin in patient

Phase II trial of carboplatin in patients with advanced germ-cell testicular tumors and transitional cell carcinomas of the urinary tract

✍ Hideyuki Akaza; Masamichi Hagiwara; Nobuhiro Deguchi; Tsuneo Kawai; Yoshiaki Sat 📂 Article 📅 1989 🏛 Springer 🌐 English ⚖ 446 KB

The role of ifosfamide plus cisplatin-ba

The role of ifosfamide plus cisplatin-based chemotherapy as salvage therapy for patients with refractory germ cell tumors

✍ Robert J. Motzer; Karen Cooper; Nancy L. Geller; Dean F. Bajorin; Ethan Dmitrovs 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 537 KB

A prospective study of four cycles of etoposide with ifosfamide and cisplatin (VIP) chemotherapy was conducted in 42 germ cell tumor (GCT) patients who were refractory to cisplatin with etoposide/vinblastine-based therapy. Forty patients were evaluable for response. Ten patients (25%) had a complete